Bosse Maxime, Lardinois Benjamin, Cadrobbi Julie, Van Eeckhoudt Sandrine, Sambon Pauline, Opsomer Gaëtan, Gras Jeremie, Mathys Vanessa, Laffineur Kim
Department of Clinical Microbiology, Clinique Saint-Luc, Bouge, Belgium.
Department of Internal Medicine, Clinique Saint-Luc, Bouge, Belgium.
Infection. 2025 Aug 25. doi: 10.1007/s15010-025-02610-z.
Osteoarticular infections caused by intravesical BCG are rare and poorly characterized. This study presents a case of acromioclavicular joint infection caused by Mycobacterium bovis BCG, alongside a systematic review aimed at improving our understanding of the infection's clinical features, diagnosis, treatment and outcomes.
This systematic review included all published cases of osteoarticular infections due to M. bovis BCG following intravesical BCG instillation, as identified through a PubMed search conducted up to 1 May 2025. The search used combinations of keywords related to 'BCG', 'bladder', and 'osteoarticular infection'. One additional case from our institution was added. Clinical, biological, radiological, treatment and outcome data were extracted and analyzed.
We reviewed 67 cases, classified as vertebral (n = 45), prosthetic joint (n = 18), and native joint (n = 4). The affected patients were predominantly men (98.5%), with a mean age of 74.1 ± 9.2 years. The median delay in months between the first instillation and the diagnosis was 23 [IQR 13.0-48.0]. Fever was uncommon (20.5%), while elevated C-reactive protein levels were frequent (80%). Imaging (CT/MRI) played a key role in diagnosis by showing images consistent with infection in all cases in which it was used. Treatment typically involved rifampicin and isoniazid for 12 months, alongside ethambutol for two months. Outcomes were favorable in 90.6% of cases, with one death attributed to the infection.
Though rare, M. bovis BCG osteoarticular infections should be considered in patients with unexplained joint symptoms following BCG therapy. Early diagnosis and appropriate therapy are essential for optimal management.
膀胱内卡介苗引起的骨关节感染罕见且特征描述不足。本研究报告了一例由牛分枝杆菌卡介苗引起的肩锁关节感染病例,并进行了系统综述,旨在提高我们对该感染的临床特征、诊断、治疗及预后的认识。
本系统综述纳入了截至2025年5月1日通过PubMed检索确定的所有膀胱内灌注卡介苗后由牛分枝杆菌卡介苗引起的骨关节感染的已发表病例。检索使用了与“卡介苗”“膀胱”和“骨关节感染”相关的关键词组合。我们机构又补充了1例病例。提取并分析了临床、生物学、放射学、治疗及预后数据。
我们回顾了67例病例,分为脊柱感染(n = 45)、人工关节感染(n = 18)和天然关节感染(n = 4)。受影响患者以男性为主(98.5%),平均年龄为74.1±9.2岁。首次灌注至诊断的中位延迟时间为23个月[四分位间距13.0 - 48.0]。发热不常见(20.5%),而C反应蛋白水平升高很常见(80%)。影像学检查(CT/MRI)在所有使用该检查的病例中均显示出与感染相符的图像,在诊断中起关键作用。治疗通常包括利福平与异烟肼联用12个月,乙胺丁醇联用2个月。90.6%的病例预后良好,1例死亡归因于该感染。
尽管罕见,但在卡介苗治疗后出现不明原因关节症状的患者中应考虑牛分枝杆菌卡介苗骨关节感染。早期诊断和适当治疗对于最佳管理至关重要。